
Vitrolife - Pressure on Growth and Margins

APAC and Consumables delivers another strong quarter with double digit growth. Vitrolife continues to experience pressure on the Genetic Services business and especially in US. Some of these challenges can be expected to remain for some time. The weakness in the Technology Business is more likely to be temporary. We can expect a near term period of more modest growth and stable margins. The consumable business and the APAC regions probably need to compensate with a solid performance also during H2 2023E. Our updated view is a base case valuation of SEK 265 (295) and a Bull Case of SEK 415 (425), and a Bear Case of SEK 130 (140). A near term balancing act.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Vitrolife - Pressure on Growth and Margins](#)